IP Licence Fee & Royalty Calculator
Calculate royalty payments for patents, trademarks, software and IP licences with industry benchmark rates
Last updated: March 2026 | UK Patent Box rate 10% | Withholding tax 20% (treaty reductions apply)
IP Royalty & Licence Fee Calculator 2026
Enter licence details to calculate annual royalty payments, NPV over 5/10 years and effective rate
Industry Benchmark Royalty Rates UK 2026
| IP Type / Sector | Typical Royalty Range | Notes |
|---|---|---|
| Pharmaceutical patents | 4–8% of net sales | Up to 15–20% for breakthrough drugs |
| Medical devices | 3–7% of net sales | Lower for commodity devices |
| Software licences | 2–10% of net sales | SaaS often per-seat or % ARR |
| Consumer brand / trademark | 4–15% of net sales | Premium brands at the top end |
| Entertainment / music copyright | 10–25% of revenues | Publisher splits vary widely |
| Manufacturing / technology | 1–5% of net sales | Know-how included separately |
| Semiconductor / electronics | 1–5% of net sales | FRAND rates for SEPs: 0.1–2% |
Complete Guide to IP Licensing and Royalty Rates UK 2026
1. OECD Transfer Pricing: Setting Arm's Length Royalty Rates
When IP is licensed between related parties (e.g. a UK parent to a subsidiary in Ireland, or a US parent to a UK subsidiary), the royalty rate must be set at the arm's length price — the price that unrelated parties would agree in comparable circumstances. This is a fundamental requirement of OECD Transfer Pricing Guidelines (OECD TPG, 2022) and UK domestic law under the Taxation (International and Other Provisions) Act 2010 (TIOPA 2010).
The primary method for IP is the Comparable Uncontrolled Transaction (CUT) method — finding genuinely comparable third-party licence agreements. Databases such as RoyaltyStat, ktMINE and BvD Amadeus IP are used to source comparables. In practice, finding truly comparable transactions for unique IP is difficult, so secondary methods are often necessary: the Profit Split method (splitting residual profits between the IP owner and the licensed entity), TNMM (Transactional Net Margin Method), or the DCF-based income method.
HMRC requires large businesses (turnover above £200m or assets above £2bn) to maintain contemporaneous transfer pricing documentation. Mid-sized businesses are not legally required to maintain TP documentation but face a higher risk of HMRC enquiry and penalties (up to £10,000 for failure to maintain records, plus tax-geared penalties of 15–30% for inaccuracies) if their pricing is subsequently challenged. The BEPS Action Plan has significantly strengthened HMRC's ability to challenge aggressive IP transfer pricing arrangements.
2. UK Patent Box: 10% Tax Rate on Qualifying IP Income
The UK Patent Box was introduced in 2013 and provides a reduced corporation tax rate of 10% on profits derived from qualifying patents. For a company paying the 25% main CT rate, this represents a 15 percentage point saving on qualifying income — equivalent to a 60% reduction in the tax on that income. The Patent Box is highly valuable for IP-intensive businesses and can significantly enhance the after-tax return on royalty income.
Qualifying IP includes: UK and European patents granted after 1 April 2013; patents granted by various other jurisdictions specified in regulations; SPCs (supplementary protection certificates); and from 1 July 2021, qualifying patents under the modified nexus approach. Trademarks, copyright and know-how do not qualify for the Patent Box — only granted patents (not applications). The IP must have been developed by the company (or acquired and enhanced) through qualifying R&D expenditure.
The modified nexus fraction introduced in 2016 limits the amount of Patent Box income that qualifies based on the proportion of R&D expenditure the company incurred directly versus R&D it acquired or outsourced. The formula is: Qualifying Income × (D + S1) / (D + S1 + S2 + A) × 1.3 (uplift for sub-contracted R&D to unrelated parties), capped at 1. Larger businesses with significant acquired IP or outsourced R&D may find a smaller proportion of their income qualifies than expected — detailed modelling is essential.
3. Royalty Withholding Tax: UK Domestic Rate and Treaty Reductions
Under Section 349 of the Income Tax Act 2007, the UK payer of a royalty to a non-UK resident must deduct 20% withholding tax (WHT) at source before remitting payment. This applies to royalties for intellectual property including patents, trademarks, copyright, design rights, and know-how. The payer must account for the withheld tax to HMRC via a quarterly return and annual NRLY form.
The WHT rate is reduced or eliminated under the UK's network of Double Tax Treaties (DTTs). Key rates: USA, Germany, France, Netherlands, Sweden, Switzerland — 0%; Japan — 0%; Ireland — 0%; India — 10–15% depending on IP type; China — 10%; Brazil — 15%; Russian Federation — 0%. Post-Brexit, the EU Parent-Subsidiary and Interest and Royalties Directives no longer apply — UK companies can no longer rely on these for zero withholding on royalties to EU group companies; they must rely on the relevant bilateral DTT instead.
From the licensor's perspective, the WHT deducted by the UK payer may be creditable against the licensor's domestic tax liability in their home country under the relevant DTT. Excess WHT that cannot be credited is an economic cost. Structuring licence flows to minimise irrecoverable WHT is a key objective in multinational IP planning. HMRC's DT treaty passport scheme allows qualifying foreign lenders and licencees to receive reduced WHT on registration, avoiding the need to reclaim overpaid WHT after the fact.
4. Royalty Stacking and Exclusivity Premium
Royalty stacking occurs in industries (particularly pharma and technology) where a single product incorporates multiple separately licensed patents or technologies, each requiring royalty payments. The cumulative royalty burden across all licences can become uneconomic — a product with 30 licensed technologies each at 2% would face a 60% total royalty burden, making profitability impossible. Managing royalty stacking is a critical concern in patent-intensive product development.
In practice, royalty stacking is addressed by: (1) Negotiating cross-licensing arrangements where companies license each other's patents on a reciprocal basis, often for nominal or zero royalties; (2) Patent pool participation (e.g. MPEG LA for video codecs, Via Licensing for audio) where all essential patents are licensed through a single entity at a pre-agreed aggregate rate; (3) Reducing per-licence rates to reflect the licensee's overall royalty burden — FRAND (Fair, Reasonable and Non-Discriminatory) licensing for standard-essential patents limits individual royalties.
The exclusivity premium is the additional royalty a licensee pays for exclusive rights. Economically, an exclusive licensee gains the right to be the sole commercialiser in a territory, preventing the licensor from licensing competitors. The premium reflects the lost opportunity cost to the licensor of not licensing others. Empirical studies suggest exclusivity commands a 20–50% premium over comparable non-exclusive licences. Exclusive licences should always have minimum royalty obligations to ensure the licensor receives a guaranteed income stream even if the licensee underperforms.
5. Territorial Licensing: UK, European and Global Strategies
IP licences can be structured on a territorial basis — granting rights in one country, a region, or globally. Post-Brexit, UK and EU protection are separate: a UK patent provides UK-only protection; a European patent (granted by the EPO) designates individual countries and can include the UK. The Unitary Patent (coming into force for EU member states) allows a single patent to cover up to 17 EU states but does not cover the UK. Businesses with European sales need both UK and EU patent strategies.
For licensing purposes, territory affects both the royalty rate and the compliance requirements. A UK-only licence avoids EU transfer pricing rules but may be of limited value if the major market is continental Europe. A global licence generates higher royalties but involves complex multi-jurisdictional WHT management, varying FRAND commitments, and different enforcement regimes. Many licensors split global rights into territories — USA, Europe, Asia-Pacific — and negotiate separately with regional licensees to capture local market value.
Minimum royalty obligations in territorial licences protect against "blocking" — where a licensee takes an exclusive licence to prevent competitors from accessing the technology but then fails to commercialise it actively. Always include: minimum annual royalties (increasing each year), a "use it or lose it" clause allowing the licensor to terminate if revenue targets are not met, milestone payments, and regular royalty audits (the right to inspect the licensee's accounts to verify reported revenues).
6. Tax Treatment: Licensor and Licensee Perspectives
For the licensor (the IP owner receiving royalties): Royalty income is trading income if licensing is the licensor's business activity, or non-trading income if occasional. Trading royalties are subject to corporation tax at 19–25% (or 10% under Patent Box for qualifying patents). Non-trading royalties (e.g. from casual licensing) may be taxed as miscellaneous income. Interest on delayed royalty payments is also taxable. The licensor must include royalties in its CT return and may claim deductions for the costs of IP development and registration.
For the licensee (paying royalties): Royalties paid under a commercial arm's length licence agreement are generally deductible as business expenses for corporation tax purposes — provided they are incurred wholly and exclusively for the purposes of the trade and are not capital in nature. Royalties for use of IP in the current trading period are revenue; payments to acquire IP are capital. The deductibility of intra-group royalties is subject to transfer pricing rules — excessive royalties paid to a related party may be disallowed.
The interaction with capital allowances is important: payments to acquire a patent outright are capital and qualifying for capital allowances at 25% p.a. on a reducing balance basis (or 100% if qualifying for Annual Investment Allowance). Know-how acquired for a lump sum is treated as a capital payment attracting a 25% WDA. Know-how licensed (ongoing royalties) is treated as revenue expenditure and fully deductible in the year incurred — an important distinction for structuring IP acquisitions.
7. IP Valuation for M&A and Transfer Pricing
When IP is transferred between group companies or sold as part of an M&A transaction, it must be valued at arm's length. The three main IP valuation methodologies are: (1) Income approach (DCF) — the NPV of expected future royalties or profits attributed to the IP, discounted at a risk-adjusted rate (typically 10–25% for patent portfolios, depending on technology maturity and commercial risk); (2) Market approach (CUT/CUP) — comparable transactions in the market, adjusted for differences in exclusivity, geography, strength of IP, and remaining patent life; (3) Cost approach (relief from royalty) — the royalties the owner would have to pay if they did not own the IP, capitalised into a present value.
For transfer pricing purposes, HMRC requires that IP valuations use the realistic alternatives framework: the price must reflect what each party would agree to, given their realistic alternatives to transacting with each other. A UK subsidiary transferring valuable IP to a low-tax jurisdiction at a below-market price will attract HMRC scrutiny, particularly following the BEPS reforms. Chapter VI of the OECD TPG on hard-to-value intangibles gives HMRC the power to adjust prices based on actual outcomes where a significant divergence from projected outcomes materialises in the three years post-transfer.
Advance Pricing Agreements (APAs) with HMRC are available for businesses that want certainty on their transfer pricing methodology for IP licences. A bilateral APA with HMRC and the counterparty's tax authority provides the strongest protection. APAs typically take 18–24 months to negotiate but provide certainty for 3–5 years. For businesses with significant IP royalty flows (£5m+ per annum), the cost of an APA is usually justified by the certainty it provides.
8. Sublicensing Rights and Revenue Sharing
An exclusive licensee who holds broad rights may wish to sublicense the IP to third parties — sharing the commercial risk while capturing licence income. The right to sublicense must be expressly granted in the licence agreement; it does not arise automatically. If sublicensing rights are included, the licence agreement should specify: the licensor's consent requirements (if any), how sublicence revenues are split between licensor and licensee, whether sublicence agreements must follow a template approved by the licensor, and the licensor's rights to audit sublicensee royalty reports.
Revenue sharing in sublicensing is typically: 50/50 (licensor gets 50% of all sublicence revenues), or 30/70 (licensor 30%, licensee 70% where the licensee invested heavily in commercial development). The commercially appropriate split reflects the relative contributions: the licensor's R&D and patent maintenance costs versus the licensee's commercialisation investment, regulatory cost and market risk.
From a tax perspective, sublicence revenues received by the primary licensee are additional income taxable in the normal way. If the primary licensee is in a tax-favourable jurisdiction (e.g. Ireland, Netherlands) and routes sublicence income through that jurisdiction, careful analysis is needed to ensure HMRC's CFC (Controlled Foreign Company) rules or the OECD Pillar Two 15% global minimum tax (effective 2024/25 in the UK) do not apply to bring the income within UK tax.
Worked Examples: IP Licence Fees and Royalty NPV
Example 1: Software Patent Licence — £500k Revenue, 5% Royalty
- Annual revenue from licensed product: £500,000
- Royalty rate: 5% | Annual royalty: £25,000
- Upfront fee: £10,000 | Licence term: 5 years
- NPV of royalties (discount rate 10%): £25,000 × 3.791 = £94,775
- Total deal value: £94,775 + £10,000 upfront = £104,775
- Patent Box (if qualifying): CT saving at 10% vs 25% = £25,000 × 15% = £3,750/year saved
- Royalty as % of profit (30% margin): 5% ÷ 30% = 16.7% of profit
Example 2: Pharmaceutical Patent — £10m Revenue, 7% Royalty, WHT 10%
- Annual revenue: £10,000,000 | Royalty rate: 7% | Annual royalty: £700,000
- Withholding tax (10% deducted by payer): £70,000
- Net royalty received: £630,000/year
- NPV over 10 years (8% discount): £700,000 × 6.710 = £4,697,000 gross NPV
- Patent Box CT saving: £700,000 × 15% = £105,000/year
- 10-year Patent Box value: £704,615 NPV (at 8% discount)
Example 3: Consumer Brand Licence — £2m Revenue, 8% Trademark Royalty
- Annual revenue: £2,000,000 | Royalty rate: 8% | Annual royalty: £160,000
- Exclusivity premium included in 8% rate | Minimum royalty: £120,000/year
- NPV over 5 years (12% discount): £160,000 × 3.605 = £576,800
- Effective rate as % of profit (35% margin): 8% ÷ 35% = 22.9% of profit
- Trademark does not qualify for Patent Box — taxed at standard CT rate
Sources & Methodology
- HMRC — Patent Box Guidance
- OECD Transfer Pricing Guidelines (2022)
- HMRC International Manual — Withholding Tax on Royalties
Disclaimer: This calculator provides indicative estimates based on published industry benchmarks. Actual royalty rates depend on IP strength, exclusivity, territory and commercial negotiation. Transfer pricing for intra-group licences requires specialist advice to comply with HMRC and OECD requirements. Always consult an IP solicitor and specialist tax adviser before entering into significant licence arrangements.